Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Theo Nicholaou"'
Autor:
Ian D. Davis, W. Hopkins, Weisan Chen, Catherine Barrow, Lloyd J. Old, Duncan MacGregor, Eric W. Hoffman, Heather Jackson, Judy Browning, Ralph Venhaus, Eugene Maraskovsky, Linda Pan, Nektaria Dimopoulos, David S. Williams, Jonathan Cebon, Theo Nicholaou
Publikováno v:
Cancer Immunology, Immunotherapy. 60:1625-1637
NY-ESO-1 protein formulated in ISCOMATRIX™ results in CD4+, CD8+ T cell and antibody-mediated immunity. We evaluated persistence of immunity, relapse-free survival and tumour antigen expression upon relapse in patients vaccinated in an earlier tria
Autor:
Immanuel F. Luescher, Bee Shin Tan, Nektaria Dimopoulos, Jonathan Cebon, Sarah E Russell, Judy Browning, Axel Hoos, Lisa M. Ebert, Ian D. Davis, Heather Jackson, Theo Nicholaou, Weisan Chen, Oliver Klein, Marina Zuber
Publikováno v:
Clinical Cancer Research. 15:2507-2513
Purpose: Ipilimumab is a monoclonal antibody that blocks the immune-inhibitory interaction between CTL antigen 4 (CTLA-4) and its ligands on T cells. Clinical trials in cancer patients with ipilimumab have shown promising antitumor activity, particul
Autor:
Ralph Venhaus, Ian D. Davis, Eric W. Hoffman, Wendie Hopkins, Nektaria Dimopoulos, Lena Miloradovic, Theo Nicholaou, Weisan Chen, Lisa M. Ebert, Bee Shin Tan, Linda Pan, Jonathan Cebon, Grant A. McArthur, Eugene Maraskovsky, Heather Jackson
Publikováno v:
Clinical Cancer Research. 15:2166-2173
Purpose: NY-ESO-1 is a highly immunogenic antigen expressed in a variety of malignancies, making it an excellent target for cancer vaccination. We recently developed a vaccine consisting of full-length recombinant NY-ESO-1 protein formulated with ISC
Autor:
Birte K. Skrumsager, Niels Møller, Jonathan Cebon, Grant A. McArthur, Peter Thygesen, Theo Nicholaou, Kresten Skak, John W Barlow, Ian D. Davis, Klaus Stensgaard Frederiksen, Dorthe Lundsgaard
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 13(12)
Purpose: Human interleukin-21 (IL-21) is a pleiotropic class I cytokine that activates CD8+ T cells and natural killer cells. We report a phase 1 study of recombinant human IL-21 in patients with surgically incurable metastatic melanoma. The primary
Publikováno v:
The Lancet. 369:1923-1924
Autor:
L. J. Old, Linda S. Pan, Lena Miloradovic, Theo Nicholaou, Weisan Chen, Jonathan Cebon, Grant A. McArthur, E. Marakovsky, W. Hopkins, Eric W. Hoffman, Ian D. Davis
Publikováno v:
Journal of Clinical Oncology. 24:2571-2571
2571 Background: NY-ESO-1 is an immunogenic “cancer-testis” (CT) antigen, expressed in many cancers including melanoma. Iscomatrix adjuvant (IMX), a saponin-based adjuvant, was formulated with NY-ESO-1 (ESO) protein (ESO/IMX). ESO/IMX was highly
Autor:
Nicholaou, Theo, Chen, Weisan, Davis, Ian, Jackson, Heather, Dimopoulos, Nektaria, Barrow, Catherine, Browning, Judy, MacGregor, Duncan, Williams, David, Hopkins, Wendie, Maraskovsky, Eugene, Venhaus, Ralph, Pan, Linda, Hoffman, Eric, Old, Lloyd, Cebon, Jonathan
Publikováno v:
Cancer Immunology, Immunotherapy; Nov2011, Vol. 60 Issue 11, p1625-1637, 13p